| Literature DB >> 31632490 |
Yaqian Han1, Qianjin Liao1, Heran Wang1, Shan Rao1, Pin Yi1,2, Lu Tang1,2, Yutong Tian1,2, Linda Oyang1, Hui Wang1, Yingrui Shi1, Yujuan Zhou1.
Abstract
Objective: Emerging evidence suggests that calreticulin (CALR) has great impacts on the tumor formation and progression of various cancers, but the role of CALR remains controversial. We investigated the expression and clinical significance of CALR in nasopharyngeal carcinoma (NPC).Entities:
Keywords: STAT3; calreticulin; nasopharyngeal carcinoma; prognosis; progression
Year: 2019 PMID: 31632490 PMCID: PMC6775705 DOI: 10.7150/jca.35362
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Relationships between expression levels of CALR and clinicopathologic characteristics
| Characteristics | Cases | CALR | ||
|---|---|---|---|---|
| High | Low | |||
| Normal | 131 | 22 | 109 | |
| Age | 0.612 | |||
| ≤48 | 66 | 10 | 56 | |
| >48 | 65 | 12 | 53 | |
| Gender: | 0.306 | |||
| Male | 95 | 14 | 81 | |
| Female | 36 | 8 | 28 | |
| Tumor | 256 | 164 | 92 | |
| Age | 0.123 | |||
| ≤48 | 125 | 86 | 39 | |
| >48 | 131 | 78 | 53 | |
| Gender: | 0.325 | |||
| Male | 200 | 125 | 75 | |
| Female | 56 | 39 | 17 | |
| Metastasis | 164 | 116 | 48 | 0.003 |
| No metastasis | 92 | 48 | 44 | |
| Stages I+II | 115 | 65 | 50 | 0.023 |
| Stages III+IV | 141 | 99 | 42 | |
Figure 1Expression of CALR in NPC tissues and cells. A: Representative IHC staining of CALR in NPC tissues (magnification×400, scale bars 20μm); B: qRT-PCR analysis of the relative expression levels of CALR in 36 NPC specimens and 15 NPE specimens; C: Detection the expression of CALR in NP69 cell line and NPC cell lines by western blotting. NPC: nasopharyngeal carcinoma, NPE: non-tumor nasopharyngeal epithelium.
Figure 2Survival analysis of patients with varying levels of CALR expression in NPC. Kaplan-Meier estimated progression-free survival (PFS) and overall survival (OS) for NPC patients according to the expression levels of CALR protein in 81 NPC patients. P values were obtained by using the log-rank test. N, The number of cases; Events, the number of cases, who had recurrent tumor or died during the follow-up period.
Cox regression analyses of the various factors associated with PFS and OS in NPC patients
| Variables | progression-free survival | overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Gender (Female/Male) | 0.546 | 0.248-1.200 | 0.132 | 0.492 | 0.221-1.096 | 0.083 |
| Age(≤48/>48) | 0.710 | 0.380-1.327 | 0.283 | 0.595 | 0.316-1.120 | 0.108 |
| Stage(I+II/III+IV) | 2.430 | 0.810-7.289 | 0.113 | 2.466 | 0.868-7.003 | 0.090 |
| Metastasis | 0.529 | 0.169-1.655 | 0.274 | 0.476 | 0.162-1.400 | 0.178 |
| CALR(High/Low) | 2.564 | 1.217-5.405 | 0.013 | 3.179 | 1.464-6.902 | 0.003 |
HR, hazard ratio; 95% CI, 95% confidence interval
Figure 3Knockdown of CALR inhibits the cell proliferation, migration and invasion of NPC cells. In order to silence the expression of CALR, CNE2 and HONE1 cells were transfected with CALR interfering plasmids (si-CALR#1, si-CALR#2). The proliferation of CNE2 and HONE1 cells was analyzed by Cck-8 assay (A), cell migration of CNE2 and HONE1 cells was analyzed using scratch wound assays (B), and further confirmed by transwell assays without a diluted Matrigel coating (C). Cell invasion of CNE2 and HONE1 cells was analyzed using transwell assays with a diluted Matrigel coating(C). Error Bar = SD, **P < 0.01, ***P < 0.001 compared to vector, independent Student's t-test.
Figure 4Knockdown of CALR suppressed the expression of Stat3 in NPC cells. The expression of CALR, Stat3 and p-Stat3 in CNE2 and HONE1 cells transfected with CALR interfering plasmids (si-CALR#1, si-CALR#2) and control vector were detected by western blotting.